Document is current
Any future updates will be listed below
-
Authors
Thompson, Keyata N.
Ju, Julia A.
Ory, Eleanor C.
Pratt, Stephen J. P.
Lee, Rachel M.
Mathias, Trevor J.
Chang, Katarina T.
Lee, Cornell J.
Goloubeva, Olga G.
Bailey, Patrick C.
Chakrabarti, Kristi R.
Jewell, Christopher M.
Vitolo, Michele I.
Martin, Stuart S. http://orcid.org/0000-0002-4378-4381
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01-CA124704, R01-CA154624, R01-EB027143)
U.S. Department of Veterans Affairs (I01-BX002746, I01-BX003690)
American Cancer Society (RSG-18-028-01-CSM, 122229-IRG-97-153-10-IRG, K01CA166575)
Division of Cancer Epidemiology and Genetics, National Cancer Institute (5T32GM008181-30, 1F31CA232393-01)
METAvivor (#637)
National Cancer Institute (P30-CA134274)
Maryland Cigarette Restitution Fund
- License Information
-
More Information
Article History
Received: 10 December 2020
Accepted: 26 January 2022
First Online: 14 February 2022
Declarations
:
: The mice used in this study were maintained in accordance with Institutional Animal Care and Use Committee procedures and guidelines at University of Maryland, Baltimore under an approved protocol.
: Not applicable.
: The University of Maryland has patents pending on the microfluidic cell tethering technology on which K.R.C, C.M.J. and S.S.M. are listed as inventors. S.S.M and C.M.J. are employees of the VA Maryland Health Care System. The views reported in this paper do not reflect the views of the Department of Veterans Affairs or the United States Government.
